Unique ID issued by UMIN | UMIN000010336 |
---|---|
Receipt number | R000012100 |
Scientific Title | Feasibility study of adjuvant chemotherapy with cisplatin and pemetrexed short hydration regimen for completely resected NSCLC |
Date of disclosure of the study information | 2013/04/01 |
Last modified on | 2018/04/17 14:48:48 |
Feasibility study of adjuvant chemotherapy with cisplatin and pemetrexed short hydration regimen for completely resected NSCLC
Feasibility study of adjuvant chemotherapy with cisplatin and pemetrexed short hydration regimen for completely resected NSCLC
Feasibility study of adjuvant chemotherapy with cisplatin and pemetrexed short hydration regimen for completely resected NSCLC
Feasibility study of adjuvant chemotherapy with cisplatin and pemetrexed short hydration regimen for completely resected NSCLC
Japan |
Completely resected NSCLC(non-squamous cell carcinoma, stage II - IIIA)
Pneumology | Chest surgery |
Malignancy
NO
The purpose of this study is to evaluate feasibility of adjuvant chemotherapy with cisplatin and pemetrexed short hydration regimen for completely resected NSCLC (non-squamaous cell carcinoma) with staged II to IIIA.
Safety
Chemotherapy compliance in the four cycles
1.safety
2.extraction rate from hospitalization to outpatient clinic
3.2-years disease free survival
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Dose:day1 CDDP 75mg/m2+PEM 500 mg/m2 with short hydration
Cycle: 4 cycles
20 | years-old | <= |
75 | years-old | >= |
Male and Female
(1)The patient histologically proven as non-small cell lung cancer
(2)The patient with p-staged II - IIIA that received segmentectomy, lobectomy, or bi-lobectomy
(3) Performance Status is 0 - 1 (ECOG).
(4) 20 years of age or older, 75 years of age or younger.
(5) The patient who does not receive any chemotherapy, radiotherapy, or immunotherapy prior to resection
(6) The patient who preserves the main organ ( the bone marrow, liver, kidney and so on )
(7) The patient who can receive chemotherapy within 4 - 8 weeks after resection
(8) The patient who gives written informed consent
(1)The patient with infection
(2)The patient with fever (equal to or more than 38 C)
(3)The patient with heavy complication
(4)The patient with active double-cancer
(5)The patient with uncontrolled pleural effuson
(6)The patient with a motor-palsy or figure of peripheral-nerve-disease
(7)The patient with drug hypersensitivity
(8)The patient with common use of NSAIDs
(9)The expectant mother, the woman who has a lactating-woman and the possibility of the pregnancy
(10)The patient judged as unsuitable by the doctor
21
1st name | |
Middle name | |
Last name | Motoko Tachihara |
Kobe University Graduate School of Medicine
Division of Respiratory Medicine, Department of Internal Medicine,
7-5-1, Kusunoki-Cho,Chuo-Ku, Kobe
078-382-5846
mt0318@med.kobe-u.ac.jp
1st name | |
Middle name | |
Last name | Motoko Tachihara |
Kobe University Graduate School of Medicine
Division of Respiratory Medicine, Department of Internal Medicine,
7-5-1, Kusunoki-Cho,Chuo-Ku, Kobe
078-382-5846
mt0318@med.kobe-u.ac.jp
Division of Respiratory Medicine, Department of Internal Medicine,Kobe University Graduate School of Medicine
Division of Respiratory Medicine, Department of Internal Medicine,Kobe University Graduate School of Medicine
Self funding
NO
2013 | Year | 04 | Month | 01 | Day |
Unpublished
Main results already published
2013 | Year | 03 | Month | 13 | Day |
2013 | Year | 04 | Month | 01 | Day |
2013 | Year | 03 | Month | 28 | Day |
2018 | Year | 04 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012100